N-Formamidopyrazoline Derivative Selective P2X3 Antagonist
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current P2X3 receptor inhibitors, such as AF-219, are effective in reducing chronic cough but often cause taste disorders due to non-selective blockade of P2X2/3 channels, leading to patient compliance issues and the need for more selective and safer therapeutic options.
Innovation Solution
Development of a novel N-formamidopyrazoline derivative with a specific compound structure that selectively inhibits P2X3 receptors, offering improved selectivity, pharmacokinetics, and pharmacodynamics, which can be used to treat diseases mediated by P2X3, including chronic cough and pain, without the side effects associated with existing inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing P2X3 receptor inhibitors (e.g., AF-219) are used to treat chronic cough and pain, then therapeutic effectiveness is improved, but taste disorders occur due to non-selective blockade of P2X2/3 channels
Solution Approach 1:
The invention segments the P2X receptor blockade into selective P2X3 inhibition while sparing P2X2/3 heteromeric channels. The compound selectively targets homomeric P2X3 receptors expressed in sensory neurons, avoiding blockade of P2X2/3 heteromeric channels in taste buds, thereby resolving the contradiction between therapeutic effectiveness and taste side effects
Solution Approach 2:
The compound exhibits local quality differences in its pharmacological action: it selectively binds to and blocks P2X3 receptors in nociceptive sensory neurons (providing analgesic and antitussive effects) while maintaining selectivity against P2X2/3 receptors in taste buds (avoiding taste disorders). This spatial and functional selectivity resolves the technical contradiction
2Productivity
If non-selective P2X2/3 channel blockade is used to achieve therapeutic effects, then pain and cough symptoms are reduced, but patient compliance deteriorates due to side effects
Solution Approach 1:
The invention changes the selectivity parameter of the P2X3 inhibitor by developing a compound with optimized molecular structure that specifically targets homomeric P2X3 receptors. This parameter change from non-selective to selective inhibition maintains symptom reduction efficacy while eliminating taste disorders, thereby improving patient compliance
3Object-affected harmful factors
If selective P2X3 inhibition is achieved through novel compound structure, then safety and selectivity are improved, but drug development complexity increases
Solution Approach 1:
The invention achieves selective P2X3 inhibition by changing molecular structure parameters of the pyrazoline derivative, specifically modifying substituents at positions R1-R6 to optimize selectivity for homomeric P2X3 receptors over P2X2/3 heteromeric channels, thereby improving safety profile while managing development complexity
Data Source
AI summary
An N-formamidopyrazoline derivative is a compound having General Formula (I) or an enantiomer, a diastereomer, an epimer and a racemate thereof, or a pharmaceutically acceptable salt thereof. The compound is an antagonist of a ligand-gated non-selective cation channel receptor subtype P2X3, and can be used for treating or preventing various diseases mediated by the receptor P2X3.